These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 33196342)

  • 1. Stumbles in Sjögren's syndrome drug development: where to look for the next big leap?
    Verstappen GM; Kroese FGM; Bootsma H
    Expert Rev Clin Immunol; 2020 Nov; 16(11):1043-1045. PubMed ID: 33196342
    [No Abstract]   [Full Text] [Related]  

  • 2. The value of rituximab treatment in primary Sjögren's syndrome.
    Verstappen GM; van Nimwegen JF; Vissink A; Kroese FGM; Bootsma H
    Clin Immunol; 2017 Sep; 182():62-71. PubMed ID: 28478105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful treatment of renal tubular acidosis and recurrent secondary struvite kidney stones with rituximab in a patient with primary Sjögren's syndrome.
    Schilcher G; Schwarz C; Hermann J
    Rheumatology (Oxford); 2017 Mar; 56(3):498-500. PubMed ID: 28031439
    [No Abstract]   [Full Text] [Related]  

  • 4. Persistence of focal lymphocytic sialadenitis in patients with primary Sjögren's syndrome treated with rituximab: a possible role for glandular BAFF.
    Carubbi F; Cipriani P; Di Benedetto P; Ruscitti P; Alunno A; Gerli R; Giacomelli R
    Clin Exp Rheumatol; 2016; 34(6):1123-1124. PubMed ID: 27494407
    [No Abstract]   [Full Text] [Related]  

  • 5. Maintenance of rituximab treatment in a patient with primary Sjögren's syndrome.
    Lehner GF; Brunner-Palka M; Rettenbacher T; Schmidauer R; Herold M
    Rheumatology (Oxford); 2014 Jul; 53(7):1349-50. PubMed ID: 24446469
    [No Abstract]   [Full Text] [Related]  

  • 6. Successful treatment of Sjogren's syndrome with rituximab.
    Touma Z; Sayad J; Arayssi T
    Scand J Rheumatol; 2006; 35(4):323-5. PubMed ID: 16882600
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment approaches in primary Sjogren syndrome.
    Vissink A; Kallenberg CG; Bootsma H
    JAMA; 2010 Nov; 304(18):2015-6; author reply 2016. PubMed ID: 21063008
    [No Abstract]   [Full Text] [Related]  

  • 8. [Efficiency of rituximab in an unusual form of primary Sjögren's syndrome: a case report].
    Mrabet D; Meddeb N; Sahli H; Saadi F; Chéour E; Elleuch M; Sellami S
    Therapie; 2010; 65(6):581-3. PubMed ID: 23189757
    [No Abstract]   [Full Text] [Related]  

  • 9. Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome.
    Bowman SJ; Everett CC; O'Dwyer JL; Emery P; Pitzalis C; Ng WF; Pease CT; Price EJ; Sutcliffe N; Gendi NST; Hall FC; Ruddock SP; Fernandez C; Reynolds C; Hulme CT; Davies KA; Edwards CJ; Lanyon PC; Moots RJ; Roussou E; Giles IP; Sharples LD; Bombardieri M
    Arthritis Rheumatol; 2017 Jul; 69(7):1440-1450. PubMed ID: 28296257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of the Sjögren's Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy.
    Cornec D; Devauchelle-Pensec V; Mariette X; Jousse-Joulin S; Berthelot JM; Perdriger A; Puéchal X; Le Guern V; Sibilia J; Gottenberg JE; Chiche L; Hachulla E; Hatron PY; Goeb V; Hayem G; Morel J; Zarnitsky C; Dubost JJ; Seror R; Pers JO; Meiners PM; Vissink A; Bootsma H; Nowak E; Saraux A
    Rheumatology (Oxford); 2015 Sep; 54(9):1699-708. PubMed ID: 25957440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Biologics in Sjögren's Syndrome.
    Nocturne G; Cornec D; Seror R; Mariette X
    Rheum Dis Clin North Am; 2016 Aug; 42(3):407-17. PubMed ID: 27431344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First report of improvement of coeliac disease in a patient with Sjögren's syndrome treated with rituximab.
    Nikiphorou E; Hall FC
    Rheumatology (Oxford); 2014 Oct; 53(10):1906-7. PubMed ID: 24729401
    [No Abstract]   [Full Text] [Related]  

  • 13. Issues related to clinical trials of oral and biologic disease-modifying agents for Sjögren's syndrome.
    Carsons SE
    Rheum Dis Clin North Am; 2008 Nov; 34(4):1011-23, x. PubMed ID: 18984419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe Health-Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient-Reported Outcomes: Data From a Large Therapeutic Trial.
    Cornec D; Devauchelle-Pensec V; Mariette X; Jousse-Joulin S; Berthelot JM; Perdriger A; Puéchal X; Le Guern V; Sibilia J; Gottenberg JE; Chiche L; Hachulla E; Yves Hatron P; Goeb V; Hayem G; Morel J; Zarnitsky C; Dubost JJ; Saliou P; Pers JO; Seror R; Saraux A
    Arthritis Care Res (Hoboken); 2017 Apr; 69(4):528-535. PubMed ID: 27390310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Treatment Guidelines for Sjögren's Disease.
    Vivino FB; Carsons SE; Foulks G; Daniels TE; Parke A; Brennan MT; Forstot SL; Scofield RH; Hammitt KM
    Rheum Dis Clin North Am; 2016 Aug; 42(3):531-51. PubMed ID: 27431353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging drugs for primary Sjögren's syndrome.
    Gandolfo S; De Vita S
    Expert Opin Emerg Drugs; 2019 Jun; 24(2):121-132. PubMed ID: 31286787
    [No Abstract]   [Full Text] [Related]  

  • 17. SER recommendations on the use of biological drugs in primary Sjögren's syndrome.
    Andréu Sánchez JL; Fernández Castro M; Del Campo Fontecha PD; Corominas H; Narváez García FJ; Gómez de Salazar JR; Rua-Figueroa Í; Abad Hernández MÁ; Álvarez Rivas MN; Montes JDP; Francisco Hernández FM; Gantes Pedraza MÁ; Greco Merino MG; Hernández MV; Navarro Compán MV; Solarte JAP; Romero Bueno FI; Park HS; Sivera Mascaró F
    Reumatol Clin (Engl Ed); 2019; 15(6):315-326. PubMed ID: 30683506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing conventional DMARD therapy for Sjögren's syndrome.
    van der Heijden EHM; Kruize AA; Radstake TRDJ; van Roon JAG
    Autoimmun Rev; 2018 May; 17(5):480-492. PubMed ID: 29526636
    [No Abstract]   [Full Text] [Related]  

  • 19. World Workshop on Oral Medicine VII: Immunobiologics for salivary gland disease in Sjögren's syndrome: A systematic review.
    Gueiros LA; France K; Posey R; Mays JW; Carey B; Sollecito TP; Setterfield J; Woo SB; Culton D; Payne AS; Lodi G; Greenberg MS; De Rossi S
    Oral Dis; 2019 Jun; 25 Suppl 1(Suppl 1):102-110. PubMed ID: 31140693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tocilizumab for refractory organising pneumonia associated with Sjögren's disease.
    Justet A; Ottaviani S; Dieudé P; Taillé C
    BMJ Case Rep; 2015 May; 2015():. PubMed ID: 25976199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.